Terms: = Breast cancer AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C
199 results:
1. shp2 potentiates anti-PD-1 effectiveness through intervening cell pyroptosis resistance in triple-negative breast cancer.
Chen C; Cheng Y; Lei H; Feng X; Zhang H; Qi L; Wan J; Xu H; Zhao X; Zhang Y; Yang B
Biomed Pharmacother; 2023 Dec; 168():115797. PubMed ID: 37913735
[TBL] [Abstract] [Full Text] [Related]
2. Dysregulated ceramides metabolism via ptpn11 exposes a metabolic vulnerability to breast cancer metastasis.
Qiao S; Wang T; Wang H
Med Oncol; 2023 Sep; 40(11):310. PubMed ID: 37773553
[TBL] [Abstract] [Full Text] [Related]
3. Anion-directed structural tuning of two azomethine-derived Zn
Pandit NR; Bej S; Das R; Ghosal N; Mondal A; Pal R; Ghosh M; Banerjee P; Biswas B
Dalton Trans; 2023 Aug; 52(32):11130-11142. PubMed ID: 37496325
[TBL] [Abstract] [Full Text] [Related]
4. PI3K inhibition circumvents resistance to shp2 blockade in metastatic triple-negative breast cancer.
Amante RJ; Jehanno C; De Silva D; Coissieux MM; Ackerknecht M; Romanet V; Sethi A; Hamelin B; Preca BT; Piscuoglio S; Ng CKY; Mohseni M; Bentires-Alj M
J Mammary Gland Biol Neoplasia; 2023 Jun; 28(1):13. PubMed ID: 37294349
[TBL] [Abstract] [Full Text] [Related]
5. Sperm protein antigen 17 and Sperm flagellar 1 cancer testis antigens are expressed in a rare case of ciliated foregut cyst of the common hepatic duct.
Grizzi F; Chiriva-Internati M; Miranda E; Zaharie R; Hajjar NA; Zaharie F; Del Arco CD; Fernández-Aceñero MJ; Bresalier RS; Moiş E
Pathol Res Pract; 2023 Jul; 247():154546. PubMed ID: 37224658
[TBL] [Abstract] [Full Text] [Related]
6. Differential dose-response effect of cyclosporine A in regulating apoptosis and autophagy markers in MCF-7 cells.
Siddiqui SS; Hodeify R; Mathew S; Alsawaf S; Alghfeli A; Matar R; Merheb M; Marton J; Al Zouabi HA; Sethuvel DPM; Ragupathi NKD; Vazhappilly CG
Inflammopharmacology; 2023 Aug; 31(4):2049-2060. PubMed ID: 37204695
[TBL] [Abstract] [Full Text] [Related]
7. Tumor Cell-Autonomous shp2 Contributes to Immune Suppression in Metastatic breast cancer.
Chen H; Cresswell GM; Libring S; Ayers MG; Miao J; Zhang ZY; Solorio L; Ratliff TL; Wendt MK
Cancer Res Commun; 2022 Oct; 2(10):1104-1118. PubMed ID: 36969745
[TBL] [Abstract] [Full Text] [Related]
8. Early Triple-Negative breast cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression.
Yeong J; Goh D; Tan TJ; Tan B; Sivaraj H; Koh V; Tatt Lim JC; Joseph CR; Ye J; Yong Tay TK; Chan Lau M; Chan JY; Ng C; Iqbal J; Teh BT; Dent RA; Tan PH
Mod Pathol; 2023 Apr; 36(4):100056. PubMed ID: 36788078
[TBL] [Abstract] [Full Text] [Related]
9. Acacetin induces sustained ERK1/2 activation and RIP1-dependent necroptotic death in breast cancer cells.
Kandhari K; Mishra JPN; Agarwal R; Singh RP
Toxicol Appl Pharmacol; 2023 Mar; 462():116409. PubMed ID: 36740148
[TBL] [Abstract] [Full Text] [Related]
10. Design and synthesis of improved active-site shp2 inhibitors with anti-breast cancer cell effects.
Lade DM; Nicoletti R; Mersch J; Agazie YM
Eur J Med Chem; 2023 Feb; 247():115017. PubMed ID: 36584630
[TBL] [Abstract] [Full Text] [Related]
11. Discovery of allosteric shp2 inhibitors through ensemble-based consensus molecular docking, endpoint and absolute binding free energy calculations.
Jama M; Ahmed M; Jutla A; Wiethan C; Kumar J; Moon TC; West F; Overduin M; Barakat KH
Comput Biol Med; 2023 Jan; 152():106442. PubMed ID: 36566625
[TBL] [Abstract] [Full Text] [Related]
12. Direct AKT activation in tumor-infiltrating lymphocytes markedly increases interferon-γ (IFN-γ) for the regression of tumors resistant to PD-1 checkpoint blockade.
Santinon F; Ezzahra BF; Bachais M; Sarabia Pacis A; Rudd CE
Sci Rep; 2022 Nov; 12(1):18509. PubMed ID: 36323740
[TBL] [Abstract] [Full Text] [Related]
13. Trastuzumab combined chemotherapy for the treatment of HER2-positive advanced gastric cancer: A systematic review and meta-analysis of randomized controlled trial.
Xue C; Xu YH
Medicine (Baltimore); 2022 Aug; 101(34):e29992. PubMed ID: 36042610
[TBL] [Abstract] [Full Text] [Related]
14. MDM2 is a Potential Target Gene of Glycyrrhizic Acid for Circumventing breast cancer Resistance to Tamoxifen: Integrative Bioinformatics Analysis.
Azzahra SNA; Hanif N; Hermawan A
Asian Pac J Cancer Prev; 2022 Jul; 23(7):2341-2350. PubMed ID: 35901340
[TBL] [Abstract] [Full Text] [Related]
15. A pan-cancer analysis confirms ptpn11's potential as a prognostic and immunological biomarker.
Cao Y; Duan H; Su A; Xu L; Lai B
Aging (Albany NY); 2022 Jul; 14(13):5590-5610. PubMed ID: 35802774
[TBL] [Abstract] [Full Text] [Related]
16. Protein Tyrosine Phosphatase shp2 Controls Interleukin-8 Expression in breast cancer Cells.
Amante RJ; Auf der Maur P; Richina V; Sethi A; Iesmantavicius V; Bonenfant D; Aceto N; Bentires-Alj M
J Mammary Gland Biol Neoplasia; 2022 Jun; 27(2):145-153. PubMed ID: 35739379
[TBL] [Abstract] [Full Text] [Related]
17. The Discovery of Potent shp2 Inhibitors with Anti-Proliferative Activity in breast cancer Cell Lines.
Ghemrawi R; Khair M; Hasan S; Aldulaymi R; AlNeyadi SS; Atatreh N; Ghattas MA
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457286
[TBL] [Abstract] [Full Text] [Related]
18. Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (shp2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative breast cancer.
Chen X; Shu C; Li W; Hou Q; Luo G; Yang K; Wu X
J Med Chem; 2022 May; 65(9):6729-6747. PubMed ID: 35447031
[TBL] [Abstract] [Full Text] [Related]
19. Targeting shp2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors.
Heynen GJJE; Lisek K; Vogel R; Wulf-Goldenberg A; Alcaniz J; Montaudon E; Marangoni E; Birchmeier W
Breast Cancer Res; 2022 Apr; 24(1):23. PubMed ID: 35365185
[TBL] [Abstract] [Full Text] [Related]
20. Clinical considerations for the design of PROTACs in cancer.
Nieto-Jiménez C; Morafraile EC; Alonso-Moreno C; Ocaña A
Mol Cancer; 2022 Mar; 21(1):67. PubMed ID: 35249548
[TBL] [Abstract] [Full Text] [Related]
[Next]
